One of the first therapeutic constructs successfully triggering NK cells via ADCC was the NKp30-Fc IgG fusion construct, targeting B7-H6 on prostate cancer cells and resulting in in vivo tumor removal in mice [39]. Here, NCR3 is linked to neoplasm.